Talquetamab Combo Yields Enduring Responses in R/R Multiple Myeloma
Combining talquetamab with teclistamab elicits responses even among those with extramedullary disease in the RedirecTT-1 trial.
Taking a Multidisciplinary Approach to Thyroid Cancer Treatment
“We are now able to increase the lifespan in some of these most deadly forms of thyroid cancer solely due to gene profiling and targeted medicine,” said Geoffrey David Young, MD, PhD, FACS.
Managing Oral and Dermatologic Adverse Effects in Multiple Myeloma
Samantha Shenoy, NP, MSN, discussed common oral and dermatologic adverse effects associated with talquetamab in patients with myeloma.
ODAC Votes Against PD-L1 as Efficacy Biomarker in Esophageal Cancers
Eleven votes were cast against the favorability of using anti–PD-1 inhibitors in patients with ESCC and a PD-L1 expression of less than 1.
Calcineurin inhibition rescues alloantigen-specific central memory T cell subsets that promote chronic GVHD
These findings demonstrate the potential risks associated with CNI-based immunosuppression in stem cell transplantation without concurrent strategies to eliminate alloreactive T cells.
A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia
In a multicenter study, researchers have a phase 1, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy, aimed at treating adults with relapsed/refractory AML.
Daratumumab Regimens Improve Depth, Durability of MRD-Negativity Rates in Newly Diagnosed Multiple Myeloma
Extended follow-up from the CASSIOPEIA trial illustrates the PFS and MRD benefits of daratumumab-based induction/consolidation and maintenance therapy.
ODAC Votes Against PD-L1 as Efficacy Biomarker in Gastric Cancers
Ten votes were cast against PD-L1 as an efficacy biomarker for therapies intended to treat patients with gastric or GEJ adenocarcinoma.
Developers Submit Supplemental NDA for Darolutamide/ADT in mHSPC
Results from the ARANOTE trial support the supplemental new drug application for darolutamide/ADT in metastatic hormone-sensitive prostate cancer.
Subgroup Analysis Data Support Daratumumab Combo PFS Benefit in NDMM
A subgroup analysis from the PERSEUS trial showed sustained PFS benefit in patients with newly diagnosed multiple myeloma receiving D-VRd.
Belantamab Combo Shows Promising Outcomes in Transplant-Eligible NDMM
Responses appear to improve over time in those with transplant-eligible newly diagnosed multiple who receive the belantamab mafodotin-based combination.
Real-world Data Supports Findings from FIGHT-202 in Cholangiocarcinoma
Data from a real-world study further illustrates clinical benefit in patients with cholangiocarcinoma receiving pemigatinib.
Uterine Transposition Aims to Preserve Fertility During Radiation
As the uterus is moved to the anterior abdominal wall, patients now have a chance of preserving their fertility during radiation therapy.
FDA Approves Osimertinib in Advanced EGFR+ NSCLC
Findings from the phase 3 LAURA trial support the approval of osimertinib for advanced EGFR-mutated NSCLC.
Ruxolitinib/Selinexor Combo Is Being Evaluated for Multiple Myeloma
Combination therapy with JAK inhibitors may help improve efficacy outcomes for patients with multiple myeloma.
Phase 3 KEYFORM-007 Misses Primary End Point in MSS mCRC
The fixed-dose combination of favezelimab and pembrolizumab did not show an improvement in overall survival compared with the standard of care in patients with metastatic CRC.
Expert Commentary on the Product Profile of Tisotumab Vedotin in Cervical Cancer
Laura Bucher-Bailey, PharmD, discussed the approval of tisotumab vedotin-tftv for patients with recurrent or metastatic cervical cancer who have had progression after chemotherapy.
Ruxolitinib Elicits Few Adverse Effects When Treating Multiple Myeloma
James R. Berenson, MD, discussed adverse effects associated with oral ruxolitinib plus selinexor in patients with multiple myeloma.
Enfortumab Vedotin Combo Earns Japanese Approval for Urothelial Carcinoma
Phase 3 EV-302 results supported the approval, showing a statically significant survival benefit compared with chemotherapy in urothelial carcinoma.
Developers Resubmit NDA for Camrelizumab Combo in Unresectable Liver Cancer
Updated findings from the CARES-310 trial support the resubmitted application for camrelizumab/rivoceranib in unresectable hepatocellular carcinoma.
Fruquintinib Approved in Japan for Unresectable Advanced or Recurrent CRC
The approval is based on results from the global phase 3 FRESCO-2 trial, which demonstrated improvement in OS in patients with refractory metastatic colorectal cancer.
Multidisciplinary Team Meetings: Barriers to Implementation in Cancer Care
Carl He, MD, explores the barriers to adherence to treatment recommendations offered by the multidisciplinary team meeting in cancer care.
Finding Mentors and Forging Connections in the Brain Cancer Field
The act of asking for help is critical to finding mentors who can help one advance in the brain cancer field, according to Yoshie Umemura, MD.
Zolbetuximab Earns European Approval in Advanced CLDN18.2+ Gastric Cancer
Data from the GLOW and SPOTLIGHT trials support the European Commission’s approval of zolbetuximab for patients with CLDN18.2-positive gastric cancer.
Anthracyclines Improve Survival at the Expense of Home Time in AML
A SEER-Medicare database analysis of patients with AML illustrates a trade-off between survival outcomes and time spent in hospitals.
Dato-DXd Misses OS End Point in TROPION-Breast01 Trial of HR+ Breast Cancer
Datopotamab deruxtecan previously showed statistically significant improvement in progression-free survival in patients with HR+, HER2-low, or HER2-negative breast cancer.
Reconsidering REMS Mandate May Improve CAR T-Cell Therapy Accessibility
Nausheen Ahmed, MD, discusses the FDA REMS mandate to help assess toxicity in patients receiving CAR T-cell therapy.
Advancing Glioblastoma Research Through a Phase 3 Niraparib Trial
Investigators of the Gliofocus trial look to set a clinically relevant “benchmark” in the glioblastoma field, according to Nader Sanai, MD.
Ovarian Function Suppression May Benefit Select Breast Cancer Populations
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Long-Term Data Affirm Enduring Responses With Teclistamab in R/R Multiple Myeloma
Amrita Y. Krishnan, MD, and Binod Dhakal, MD, gave a high-level overview of teclistamab use in the MajesTEC-1 trial.
